This article provides an overview of IDH mutant gliomas, standard of care treatment, and novel therapeutic strategies, including IDH inhibitors, agents targeting DNA repair mechanisms and epigenetic vulnerabilities, and immunotherapy. The gene discussed is IDH2; the disease is glioma.